Atsushi Fushimi
Overview
Explore the profile of Atsushi Fushimi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
480
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kikuchi R, Kubota H, Nishimura Y, Gomisawa K, Kobayashi K, Otani T, et al.
Pathol Int
. 2025 Mar;
PMID: 40042127
Tumor-infiltrating lymphocyte (TIL) scoring in tumor specimens has gained increasing attention in determining patients who are likely to benefit from immunotherapies. However, the histological evaluation methods of TILs in breast...
2.
Katori H, Fushimi A, Fujimura S, Kudo R, Kamio M, Nogi H
3D Print Med
. 2024 Dec;
10(1):41.
PMID: 39630321
Breast cancer screening is implemented as part of governmental healthcare policy in many countries. While breast imaging tests contribute to reducing mortality, some breast cancers may emerge between these screenings....
3.
Kudo R, Safonov A, Jones C, Moiso E, Dry J, Shao H, et al.
Cancer Cell
. 2024 Nov;
42(11):1983.
PMID: 39532066
No abstract available.
4.
Kudo R, Safonov A, Jones C, Moiso E, Dry J, Shao H, et al.
Cancer Cell
. 2024 Oct;
42(11):1919-1935.e9.
PMID: 39393354
Inhibition of CDK4/6 kinases has led to improved outcomes in breast cancer. Nevertheless, only a minority of patients experience long-term disease control. Using a large, clinically annotated cohort of patients...
5.
Ozawa H, Haratake N, Nakashoji A, Daimon T, Bhattacharya A, Wang K, et al.
Biomedicines
. 2024 Jul;
12(7).
PMID: 39062082
Patients with pancreatic neuroendocrine tumors (pNETs) have limited access to effective targeted agents and invariably succumb to progressive disease. MUC1-C is a druggable oncogenic protein linked to driving pan-cancers. There...
6.
Bhattacharya A, Wang K, Penailillo J, Chan C, Fushimi A, Yamashita N, et al.
Oncogene
. 2024 May;
43(28):2199-2214.
PMID: 38802648
The MUC1 gene evolved in mammals for adaptation of barrier tissues in response to infections and damage. Paraspeckles are nuclear bodies formed on the NEAT1 lncRNA in response to loss...
7.
Nakashoji A, Haratake N, Bhattacharya A, Mao W, Xu K, Wang K, et al.
Cancer Res Commun
. 2024 Apr;
4(5):1268-1281.
PMID: 38619287
Significance: This work reports a previously unrecognized role for MUC1-C in driving STAT1-mediated chronic inflammation with the progression of HNSCC and identifies MUC1-C as a druggable target for advanced HNSCC...
8.
Iesato A, Fushimi A, Tahara R, Terada M, Iwase M, Kawamura C, et al.
Breast Cancer
. 2023 Nov;
31(1):63-74.
PMID: 37995024
Background: The internet, especially YouTube, has become a prominent source of health information. However, the quality and accuracy of medical content on YouTube vary, posing concerns about misinformation. This study...
9.
Yamashita N, Withers H, Morimoto Y, Bhattacharya A, Haratake N, Daimon T, et al.
iScience
. 2023 Nov;
26(11):108168.
PMID: 37915591
Activation of the MUC1-C protein promotes lineage plasticity, epigenetic reprogramming, and the cancer stem cell (CSC) state. The present studies performed on enriched populations of triple-negative breast cancer (TNBC) CSCs...
10.
Bhattacharya A, Fushimi A, Wang K, Yamashita N, Morimoto Y, Ishikawa S, et al.
Commun Biol
. 2023 Oct;
6(1):1030.
PMID: 37821650
Chronic inflammation promotes epigenetic reprogramming in cancer progression by pathways that remain unclear. The oncogenic MUC1-C protein is activated by the inflammatory NF-κB pathway in cancer cells. There is no...